Raymond James Financial’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$328M Buy
11,674,216
+187,503
+2% +$4.99M 0.1% 175
2025
Q4
$286M Sell
11,486,713
-9,541
-0.1% -$241K 0.09% 197
2025
Q3
$293M Buy
11,496,254
+710,057
+7% +$17.5M 0.09% 194
2025
Q2
$261M Sell
10,786,197
-101,080
-0.9% -$2.36M 0.09% 206
2025
Q1
$276M Buy
10,887,277
+533,173
+5% +$14M 0.1% 183
2024
Q4
$275M Buy
+10,354,104
New +$281M 0.1% 182

Other funds holding PFE

Raymond James Financial's PFE Position: Q1 2026 in Review

Raymond James Financial increased its Pfizer (PFE) stake by 1.6% in Q1 2026, buying an estimated $4.99M and bringing the position to 11,674,216 shares worth $328M. The position accounts for 0.1% of the portfolio, ranked #175.

Raymond James Financial first reported a position in PFE in Q4 2024 and has held it in 6 quarters since. 2,946 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Raymond James Financial held 11,674,216 shares of Pfizer worth $328M as of Q1 2026.
  • Raymond James Financial bought 187,503 Pfizer shares in Q1 2026, an estimated $4.99M.
  • Pfizer made up 0.1% of Raymond James Financial's portfolio in Q1 2026, its #175 holding.
  • Raymond James Financial first reported a position in Pfizer in Q4 2024 and has held it in 6 quarters since.
  • 2,946 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.